NCT03822117

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 111 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.

Conditions

• Solid Tumor Malignancy

Interventions

Type	Name	Description
DRUG	Pemigatinib	Pemigatinib administered orally once daily (QD).

Timeline

• Start date: 2019-10-17
• Primary completion: 2022-03-29
• Completion: 2022-03-29
• First posted: 2019-01-30
• Last updated: 2025-11-04
• Results posted: 2023-03-15

Locations

90 sites across 11 countries: United States, Denmark, France, Germany, Israel, Italy, Japan, South Korea, Spain, Switzerland, United Kingdom

Regulatory

• FDA-regulated drug study